Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163488 · ClinicalTrials.gov registry record · Phase 3
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT00163488 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 106 participants.
The verdict
NCT00163488, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of combined ciclesonide nasal spray administered along with a fixed combination of inhaled fluticasone dipropionate/salmeterol.
Interventions
- DRUG Ciclesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00163488
The ClinicalTrials.gov registry entry for NCT00163488 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ciclesonide is the first listed.
NCT00163488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00163488 about?
NCT00163488 is a clinical study titled "Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)". The purpose of this study is to evaluate the safety and tolerability of combined ciclesonide nasal spray administered along with a fixed combination of inhaled fluticasone dipropionate/salmeterol.
What is the current status of trial NCT00163488?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2005-01. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00163488?
The interventions under investigation include: Ciclesonide (DRUG).
Who is sponsoring clinical trial NCT00163488?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.